Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies]
Fiche du document
24 février 2021
- doi: 10.53738/REVMED.2021.17.727.0378
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.727.0378
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33625802
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_21FE0DE609F24
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
PatientesCiter ce document
M. Scheen et al., « Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.727.0378
Métriques
Partage / Export
Résumé
SGLT2 inhibitors (SGLT2i) will change the clinical practice of nephrology with their therapeutic cardiorenal and antidiabetic properties. By inhibiting proximal tubular sodium and glucose reabsorption, these new drugs decrease intraglomerular pressures. Over the last 5 years several breakthrough studies have demonstrated the SGLT2i protective effects on outcomes such as cardiovascular mortality, hospital admission for heart failure, sustained decreases in eGFR in patients with diabetic nephropathy and the development of ESKD. With the new DAPA-CKD study revealing protective effects of SGLT2i in CKD patients without diabetes, therapeutic recommendations will now have to evolve towards including these drugs in the chronic management of all most proteinuric CKD patients.